Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Formoterol group:formoterol
Budesonide/Formoterol group:Budesonide/Formoterol
Sponsors
Zhongshan Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. patients who first diagnosed COPD with FEV1/FVC <70% and 30%<=FEV1%<80%predicted, 15min after bronchodilator Salbutamol 400ug inhalation;no respiratory failure; 2. age 40-75 years old, no gender limitation; 3. patients know how to use inhalation equipment, and never used long-term bronchodilator within 4 weeks; 4. no COPD exacerbation within 4 weeks; 5. voluntarily participated and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. patients who had acute and/or chronic pulmonary diseases such as asthma which might impair lung function; 2. accepted the systemic glucocorticoid treatment within 1 month; 3. now accepting tiotropium bromide, formoterol or budesonide/formoterol treatment alone or jointly; 4. patients who now accepting short-term anticholinergics treatment alone or jointly must stop at least 1 week; 5. patients who had COPD exacerbation or used antibiotics within 1 month; 6. be allergic to tiotropium bromide, formoterol, budesonide/formoterol and inhalation lactose; 7. patients who had malignant tumor, severe dysfunction of kidney, heart and liver; 8. patients who had active tuberculosis; 9. mental disease or cognitive disorders who couldn't finish questionnaire; 10. patients with Narrow-angleglaucoma, severe BPH and bladder-neck obstruction; 11. patients who attended other clinical trial within 3 months; 12. not suitable for this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| increased FEV1 absolute value; | — |
Countries
China
Contacts
Public ContactYuanlin Song
Outcome results
None listed